(Q36505513)

14 August 2017

1 reference

title

Evidence base for using corticosteroids to treat HIV-associated immune reconstitution syndrome (English)

1 reference

14 August 2017

Emil Lesho

1

1 reference

14 August 2017

1 June 2006

1 reference

Expert Review of Anti-infective Therapy

14 August 2017

1 reference

14 August 2017

4

1 reference

14 August 2017

3

1 reference

14 August 2017

469-478

1 reference

Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals

14 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.469

Establishment of a public antiretroviral treatment clinic for adults in urban Botswana: lessons learned

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.469

Lessons learned from use of highly active antiretroviral therapy in Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.469

Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.469

Immune restoration disease after antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.469

Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.469

Issues in the management of HIV-related tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.469

Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.469

Paradoxical worsening of tuberculosis in HIV-infected persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.469

Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.469

Outcome of HIV-associated tuberculosis in the era of highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.469

Tegumentary leishmaniasis as a manifestation of immune reconstitution inflammatory syndrome in 2 patients with AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.469

Immune reconstitution syndrome due to bacillus Calmette-Guérin after initiation of antiretroviral therapy in children with HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.469

Nontuberculous mycobacterial immune reconstitution syndrome in HIV-infected patients: spectrum of disease and long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.469

Immunorestitution disease involving the innate and adaptive response

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.469

Clinical indicators of immune restoration following highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.469

Clinical management of tuberculosis in the context of HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.469

Placebo-controlled trial of prednisone in advanced HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.469

DHEA treatment for HIV+ patients: effects on mood, androgenic and anabolic parameters.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.469

Double-blind placebo-controlled trial of oral dehydroepiandrosterone in patients with advanced HIV disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.469

A study of the immunology, virology, and safety of prednisone in HIV-1-infected subjects with CD4 cell counts of 200 to 700 mm(-3).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.469

Mycobacterial lymphadenitis associated with the initiation of combination antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.469

Localized osteomyelitis due to Mycobacterium avium complex in patients with Human Immunodeficiency Virus receiving highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.469

Incidence and risk factors for immune reconstitution inflammatory syndrome in an ethnically diverse HIV type 1-infected cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.469

Immune reconstitution syndrome after highly active antiretroviral therapy in human immunodeficiency virus-infected thai children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.469

Immune reconstitution inflammatory syndrome in HIV-infected patients with mycobacterial infections starting highly active anti-retroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.469

Immune reconstitution inflammatory syndrome in HIV-infected patients with disseminated histoplasmosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.469

The role of immune reconstitution inflammatory syndrome in AIDS-related Cryptococcus neoformans disease in the era of highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.469

Contrast-enhancing progressive multifocal leukoencephalopathy as an immune reconstitution event in AIDS patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.469

Incidence of immune recovery vitritis in cytomegalovirus retinitis patients following institution of successful highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.469

The Effect of Highly Active Antiretroviral Therapy-Induced Immune Reconstitution on Development and Outcome of Progressive Multifocal Leukoencephalopathy: Study of 43 Cases with Review of the Literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.469

Rheumatic complications of human immunodeficiency virus infection in the era of highly active antiretroviral therapy: emergence of a new syndrome of immune reconstitution and changing patterns of disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.469

Fatal immune restoration disease in human immunodeficiency virus type 1-infected patients with progressive multifocal leukoencephalopathy: impact of antiretroviral therapy-associated immune reconstitution

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.469

Paradoxical reactions in HIV and pulmonary TB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.469

Progressive multifocal leukoencephalopathy after initiation of highly active antiretroviral therapy in a child with advanced human immunodeficiency virus infection: a case of immune reconstitution inflammatory syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.469

Immune reconstitution inflammatory syndrome in HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.469

A randomized, double-blind, placebo-controlled trial of the use of prednisolone as an adjunct to treatment in HIV-1-associated pleural tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.469

Military tuberculosis with paradoxical expansion of intracranial tuberculomas complicating human immunodeficiency virus infection in a patient receiving highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.469

Mycobacterial cutaneous manifestations: a new sign of immune restoration syndrome in patients with acquired immunodeficiency syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.469

Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.469

Mycobacterial Lymphadenitis after Initiation of Highly Active Antiretroviral Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.469

Mycobacterium avium complex lymph node abscess after use of highly active antiretroviral therapy in a patient with AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.469

Highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.469

Regional Bacillus Calmette-Guérin lymphadenitis after initiating antiretroviral therapy in an infant with human immunodeficiency virus type 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.469

Immunoadjuvant prednisolone therapy for HIV-associated tuberculosis: a phase 2 clinical trial in Uganda.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.469

Adult respiratory distress syndrome as a severe immune reconstitution disease following the commencement of highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.469

Inflammatory bowel perforation during immune restoration after one year of antiretroviral and antituberculous therapy in an HIV-1-infected patient: report of a case

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.469

Cerebral mycobacterium avium infection in an HIV-infected patient following immune reconstitution and cessation of therapy for disseminated mycobacterium avium complex infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.469

HIV1 and the gut in the era of highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.469

Intramedullary abscess resulting from disseminated cryptococcosis despite immune restoration in a patient with AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.469

Paradoxical recurrent meningitis following therapy of cryptococcal meningitis: an immune reconstitution syndrome after initiation of highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.469

Progressive multifocal leucoencephalopathy with unusual inflammatory response during antiretroviral treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.469

Chronic erosive herpes simplex virus infection of the penis, a possible immune reconstitution disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.469

Herpes zoster as an immune reconstitution disease after initiation of combination antiretroviral therapy in patients with human immunodeficiency virus type-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.469

Deterioration of disseminated cutaneous Mycobacterium avium complex infection with a leukaemoid reaction following institution of highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.469

Development of multiple abscesses in an HIV/TB co-infected patient after initiation of antituberculous and highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.469

Paradoxical reactions during tuberculosis treatment in patients with and without HIV co-infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.469

Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: an immune restoration disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.469

Sarcoidosis and interstitial nephritis in a child with acquired immunodeficiency syndrome: implications of immune reconstitution syndrome with an indinavir-based regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.469

Reiter's syndrome as a manifestation of an immune reconstitution syndrome in an HIV-infected patient: successful treatment with doxycycline

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.469

Compartmentalization of the immune response in varicella zoster virus immune restoration disease causing transverse myelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.469

Pulmonary Mycobacterium celatum immune restoration disease: immunopathology and response to corticosteroid therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.469

Parvovirus B19 encephalitis presenting as immune restoration disease after highly active antiretroviral therapy for human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.469

Hepatitis B virus DNA contains a glucocorticoid-responsive element

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.469

21 January 2018

Identifiers

DOI

10.1586/14787210.4.3.469

1 reference

14 August 2017

1 reference

PubMed ID

16771623